US recruitment milestone for trial of Immuron's Travelan
Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan.
https://biotechdispatch.com.au/news/us-recruitment-milestone-for-trial-of-immurons-travelan
Filter by Year:
- Immuron working towards US FDA approval of Traveler’s Diarrhea product Travelan
- US recruitment milestone for trial of Immuron's Travelan
- Immuron grows revenue by 153% in H1 FY23 with more growth catalysts lined up
- Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under
- Innovation begins with collaboration: Steven Lydeamore
- Immuron Limited Announces Participation in the LD Micro Invitational XIII
- Immuron to go ahead with IMM-529 cGMP manufacturing and proceed with FDA pre-IND submission
- Immuron Sees Substantial Sales Growth in FY23 Driven by Resurgence in Travel (ASX:IMC)
- Immuron on How their Gastrointestinal and Digestive Health Immune Supplements Work + FY23 Sales
- Sequire Spotlight Presents Immuron Limited (IMRN): Creating New Products for Infectious Diseases
- Q&A with Steven Lydeamore, CEO of Immuron Limited
- Immuron hails record monthly sales of Travelan
- Beating bacteria just got boosted
- Clinical data imminent!
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
